detailed analysis:-
📌Accent Microcell's customers come from 45 different countries:- US , Canada , Germany , UK , Japan , China , Australia , Korea , Netherlands , Turkey , Vietnam , Italy , Indonesia , Poland , Egypt , France , Thailand , New Zealand , Brazil , Russia , Mexico , Chile , Zimbabwe , Denmark , Greece and many others.🔥🔥
📌ACE investor Manoj Agarwal✅ has taken 1.25L Preferential shares on August 21, 2023.(@ Rs.50)🚀🚀
📌📌 ➡️ ➡️
▪️Accent Microcell Limited✅ founded in 2012, manufactures cellulose-based excipients for pharmaceutical, nutritional supplements, food, cosmetics, and other industries.
▪️The company manufactures over 22 grades of MCC with particle sizes ranging from 20 to 180 microns.
▪️(MCC is an odorless, fine white powder & a purified form of cellulose, which is derived from refinement of highly purified wood pulp. It is widely used as texturizer, anticaking agent, binder, lubricant, a bulking agent, and diluent)
📍It is one of the Global leading manufacturers✅ of Microcrystalline Cellulose (MCC) (*Source: Research Report on Global Microcrystalline Cellulose (MCC) Industry). The Company has carved a niche in the production of high-quality cellulose-based excipients, that meet international quality standards.
▪️AML also manufactures co-processed excipients(unique formulations) and To meet the rising demand for co-processed excipients, the company offers "accel SMCC" as product, which is a co-processed blend of Microcrystalline Cellulose (MCC) & Colloidal Silicon Dioxide and it also offer "RC" as a product, which is a co-processed blend of Microcrystalline Cellulose with Carboxy Methyl Cellulose, to cater the growing market of the co-processed excipients.💫
📌The company's product portfolio includes:-
➢Under the Accel/Vincel brand names: Microcrystalline Cellulose (MCC) - Spray Dried/ Spin Flash Dried, Microcrystalline Cellulose Spheres (MCC Spheres), Silicified Microcrystalline Cellulose (SMCC), Powdered Cellulose (PC), Microcrystalline Cellulose with Carboxy Methyl Cellulose (Co-Processed).
➢Under the brand name Acrocell: Croscarmellose Sodium (CCS).
➢Under the brand name Maccel: Magnesium Stearate (Mg. St.).
📌Accent Microcell has two manufacturing facilities with a capacity of 8,000 metric tonnes✅:-
▪️Unit I:- Pirana facility is geared towards manufacturing MCC, SMCC, PC, and MCC with CMC (mostly domestic mkt).🔥
▪️Unit II:- Dahej SEZ facility is geared towards manufacturing MCC, MCC sphere, SMCC, and MCC with CMC for export to overseas customers.🔥
▪️Capacity Utilization:- 95-100%✅
▪️Their quality control process has resulted in certifications and approvals such as EXCiPACT, US-DMF, GMP, ISO 9001:2008, HACCP, KOSHER, HALAL & USP/NF, EP, BP, JP, IP, FCC, FSSC-22000, FSSAI etc.🔥
📌📌
▪️IPO price: Rs.140
▪️IPO size: 78.4CR
▪️CMP:Rs.315
▪️Market cap: 663 CR
▪️P/E: 24✅
▪️EPS:Rs.13.4 (annualized)
▪️52 Wk High:315
▪️52 Wk Low:285
▪️ROE: 34.11%
▪️ROCE: 26.46%
▪️RoNW: 29.44%
▪️Debt/Equity: 0.52
▪️Assets:122.15Cr
▪️Total Borrowing:21Cr (Reserves and Surplus:38.31Cr)
▪️Share Holding Pre Issue:73.13%
▪️Share Holding Post Issue:53.67%
📌FINANCIALS:
▪️FY24Q1 Rev: 59.9Cr🔥
▪️FY24Q1 PAT: 7.05 Cr🔥
▪️FY23 revenue is 206.96 CR as compared to 167.53 CR(FY22), 24%✅ growth yoy.
▪️FY23 PAT is 13.01 CR as compared to 5.89 CR(FY22), 120%✅ growth yoy.
▪️54%🔥 growth in revenue in last 2 years.
▪️171%🔥 growth in PAT in last 2 years.
(PAT margins of 3.62% (FY21), 3.56% (FY22), 6.37% (FY23), 12.00% (Q1-FY24)✅)
▪️REVENUE breakup:-
➢Pharmaceuticals- 72.74%
➢Nutraceuticals- 10.52%
➢Food- 16.73%
▪️PAT projections based on industry information and investor chatter:-
➢FY24: 28-30Cr
➢FY25: 33-35Cr
➢FY26: 80-100Cr 🔥
📌IPO funds:
From the net proceeds of the IPO funds, it will utilize Rs. 54.39Cr✅ for capital expenditure required for setting up plant (2400MTPA) at Navagam - Kheda, Gujarat for manufacturing Croscarmellose Sodium (CCS), Sodium Starch Glycolate and Carboxymethylcellulose (CMC), and the rest for general corporate purposes.
➢commercial production to start from March, 2025.🔥
📌PEERS:
The company has shown Sigachi Ind. As their listed peer. It is trading at a P/E of 43.51✅ (as of December 06, 2023). However, they are not truly comparable on an apple-to- apple basis.
📌CLIENTS:
Maruti Pharma Chem Pvt Ltd ,Direct Food Ingredients Limited, Pragati Raw Pharma Pvt Ltd, Jainishk Industries etc.
📌SECTOR GROWTH:
▪️The global microcrystalline cellulose (mcc) market was valued at $401.1 million in 2021, and is projected to reach $712.9 million by 2031, growing at a CAGR of 5.9% from 2022 to 2031.✅
▪️Pharmaceuticals Market size was valued at USD 209.85 billion in 2021 and is poised to grow from USD 222.4 billion in 2022 to USD 352.98 billion by 2030, growing at a CAGR of 5.9% in the forecast period (2023-2030).✅
▪️Market size of India pharmaceuticals industry is expected to reach US$ 65 billion by 2024, and ~US$ 130 billion by 2030. According to the government data, the Indian pharmaceutical industry is worth approximately US$ 50 billion with over US$ 25 billion of the value coming from exports.✅
▪️Robust demand for microcrystalline cellulose in personal care and cosmetic industry.💫
▪️ The Asia Pacific is emerging as the market leader for the microcrystalline cellulose (MCC) industry. This is attributed to the fast-growing population in the developing economies.🔥
📌STRENGTH:
➢Well versed and equipped with advance technology.💫
➢One of the leading manufacturers of MCC (cellulose based excipient) with over two decades experience.✅
➢Established Global presence.✅
➢Experienced Promoter and management team with strong industry expertise and successful track record.
➢Long term relationship with clients and repeat & diversified business.
➢Quality Certifications.✅
📌FUTURE PLAN:
▪️Establishing New Facility to meet the rising demand for CCS, SSG, and CMC.✅
▪️Increasing our Global presence.🔥
▪️Focus on quality.
▪️Diverse Product Portfolio & Quality Services.💫
📌Disclosure: Not a buy recommendation. only for study and education purpose. Please consult your financial advisor before investing. Please stop investing blindly. I have bought few lots at Rs.300.